Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > BUSINESS
BUSINESS
- Moderna Snags Tokyo Upstart in Its 1st M&A Deal, Staff to Join Japan Unit
January 6, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Steve Sugino Becomes New CEO of BMS Japan
January 5, 2023
- Japan Likely to See Generic Listing for Azilva, Zytiga in 2023; Xarelto AG Rivals Too
January 5, 2023
- Sun Pharma Japan Gearing Up Sales of Flagship Dermatology Med Ilumya: President
December 28, 2022
- RaQualia, Veritas Seal mRNA Drug Discovery Collaboration
December 28, 2022
- PeptiDream, Lilly Ink Collab with Up to US$1.2 Billion in Milestones
December 27, 2022
- Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
December 27, 2022
- SymBio, Eagle Take Pfizer Japan to Court after Treakisym Gx Launch
December 27, 2022
- Towa Hopes to Resume Meropenem 0.5 g Shipment in March
December 27, 2022
- AnGes to Invest US$2 Million in Canada’s Vasomune
December 27, 2022
- CureApp to Kick Off Japan PIII Study of Alcohol Addiction Therapeutic App in January
December 27, 2022
- Eisai Begins Data Submission for AD Med Lecanemab in China
December 26, 2022
- Eisai Issues Statement after 3rd Death Potentially Tied to Lecanemab Reported
December 26, 2022
- Shionogi JV, Shanghai Pharma Ink Xocova Import Pact in China
December 26, 2022
- Sanofi Launches Cablivi in Japan for Acquired TTP
December 26, 2022
- Opdivo-Chemo Combo Fails in Asian Adjuvant Study for Gastric Cancer
December 26, 2022
- Yescarta Gets Second-Line Nod for Large B-Cell Lymphoma in Japan
December 26, 2022
- PeptiDream, US Merck Strike Deal on PDC Development
December 23, 2022
- Kaken Subsidiary Hits PII Goal for Vascular Malformation Drug
December 23, 2022
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…